Brookstone Capital Management’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-14,868
Closed -$967K 800
2022
Q2
$967K Buy
+14,868
New +$944K 0.02% 411
2015
Q4
Sell
-331,194
Closed -$16.3M 497
2015
Q3
$16.3M Sell
331,194
-597
-0.2% -$34.2K 2.96% 10
2015
Q2
$19.3M Buy
331,791
+14,223
+4% +$831K 2.43% 4
2015
Q1
$18.3M Buy
317,568
+8,469
+3% +$463K 2.76% 7
2014
Q4
$15.6M Buy
+309,099
New +$15.1M 2.59% 8

Other funds holding IHE

Brookstone Capital Management's IHE Position: Q3 2022 in Review

Brookstone Capital Management sold out of iShares US Pharmaceuticals ETF (IHE) in Q3 2022, closing a stake of 14,868 shares — an estimated $967K sold.

Brookstone Capital Management first reported a position in IHE in Q4 2014 and held it in 5 quarters. The position peaked at $19.3M in Q2 2015. 113 funds tracked by Wall St. Rank hold IHE as of Q3 2022.

  • Brookstone Capital Management reported no remaining iShares US Pharmaceuticals ETF position as of Q3 2022 after selling out during the quarter.
  • Brookstone Capital Management sold 14,868 iShares US Pharmaceuticals ETF shares in Q3 2022, an estimated $967K.
  • Brookstone Capital Management first reported a position in iShares US Pharmaceuticals ETF in Q4 2014 and held it in 5 quarters.
  • Brookstone Capital Management's iShares US Pharmaceuticals ETF position peaked at $19.3M in Q2 2015.
  • 113 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q3 2022.

Based on Brookstone Capital Management's 13F filing for Q3 2022, filed 14 Oct 2022.